Sionna Therapeutics (SION) shares plummeted approximately 92%. The company's experimental cystic fibrosis drug, SION-719, failed a Phase 2a clinical trial. The study evaluated SION-719 as an add-on therapy to the standard of care, Trikafta.
The drug failed to achieve a significant reduction in sweat chloride, a key disease biomarker. Sionna will halt the development of SION-719 in this specific setting. The company is re-evaluating its development pipeline, including the SION-451 compound.
Management plans to implement measures to preserve its capital. Multiple analysts downgraded the stock following the announcement. Analysts cited the trial failure and increased uncertainty regarding the company's scientific platform.